Evoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017 Read more about Evoke Pharma's Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017
Evoke Pharma Reports Fourth Quarter and Full Year 2016 Results Read more about Evoke Pharma Reports Fourth Quarter and Full Year 2016 Results
Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results Read more about Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter and Full-Year 2016 Financial Results
Evoke Pharma Announces Full Exercise of Underwriter's Option to Purchase Additional Shares Read more about Evoke Pharma Announces Full Exercise of Underwriter's Option to Purchase Additional Shares
Evoke Pharma Announces Pricing of Public Offering of Common Stock Read more about Evoke Pharma Announces Pricing of Public Offering of Common Stock
Evoke Pharma Announces Proposed Public Offering of Common Stock Read more about Evoke Pharma Announces Proposed Public Offering of Common Stock
FDA Exempts Evoke from Requirement for Human Factor Validation Study Read more about FDA Exempts Evoke from Requirement for Human Factor Validation Study
Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference Read more about Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference
Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial Read more about Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial
Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti Read more about Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti